statement from fda commissioner scott gottlieb, m.d., on unprecedented new efforts to support development of over-the-counter naloxone to help reduce opioid overdose deaths
fda's global efforts to protect patients and consumers from unsafe products
president's fiscal year 2019 budget request for fda - house testimony
fda finalizes guidances to accelerate the development of reliable, beneficial next generation sequencing-based tests
statement from fda commissioner scott gottlieb, m.d., on fda’s efforts to enhance the patient perspective and experience in drug development and review
fda expands approval of replacement heart valve, smallest mechanical valve size approved in the world
fda authorizes, with special controls, direct-to-consumer test that reports three mutations in the brca breast cancer genes
statement from fda commissioner scott gottlieb, m.d. responding to report from gao and updating on fda’s ongoing efforts to increase access to complex generic drugs
statement from fda commissioner scott gottlieb, m.d. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing fda’s new drug review programs
hangzhou adamerck pharmlabs inc telephone / fax：86-571-8534 1830 e-mail：international co-operation：global@adamerck.com
domestic cooperation：info@adamerck.com address：building 7, no. 39 xiangyuan road, gongshu district, hangzhou, zhejiang
凯发k8国际 copyright 2016 ：hangzhou adamerck pharmlabs inc
